STAIR X: Emerging Considerations in Developing and Evaluating New Stroke Therapies

Stroke. 2018 Sep;49(9):2241-2247. doi: 10.1161/STROKEAHA.118.021424.

Authors

David S Liebeskind¹, Colin P Derdeyn², Lawrence R Wechsler³; STAIR X Consortium

Collaborators

Affiliations

¹ From the Neurovascular Imaging Research Core and UCLA Stroke Center, Department of Neurology, University of California, Los Angeles (D.S.L.).
² Departments of Radiology and Neurology, University of Iowa Hospitals and Clinics (C.P.D.).
³ Department of Neurology, University of Pittsburgh Medical Center, PA (L.R.W.).

PMID: 30355006
DOI: 10.1161/STROKEAHA.118.021424

No abstract available

Keywords: biomarkers; ischemia; precision medicine; stem cells; stroke.

MeSH terms

Biomarkers
Cerebral Angiography
Device Approval*
Education
Endovascular Procedures
Guidelines as Topic
Humans
Intracranial Hemorrhages
Precision Medicine
Randomized Controlled Trials as Topic
Registries*
Research Design*
Stroke / therapy*
Thrombectomy
Thrombolytic Therapy
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Biomarkers